Search

Your search keyword '"Jutel, M."' showing total 669 results
Start Over Author "Jutel, M."
669 results on '"Jutel, M."'

51. Spices to Control COVID-19 Symptoms: Yes, but Not Only

Author

Bousquet, J. Czarlewski, W. Zuberbier, T. Mullol, J. Blain, H. Cristol, J.-P. De La Torre, R. Le Moing, V. Lozano, N.P. Bedbrook, A. Agache, I. Akdis, C.A. Canonica, G.W. Cruz, A.A. Fiocchi, A. Fonseca, J.A. Fonseca, S. Gemicioǧlu, B. Haahtela, T. Iaccarino, G. Ivancevich, J.C. Jutel, M. Klimek, L. Kuna, P. Larenas-Linnemann, D.E. Melén, E. Okamoto, Y. Papadopoulos, N.G. Pfaar, O. Reynes, J. Rolland, Y. Rouadi, P.W. Samolinski, B. Sheikh, A. Toppila-Salmi, S. Valiulis, A. Choi, H.-J. Kim, H.J. Anto, J.M.

Abstract

There are large country variations in COVID-19 death rates that may be partly explained by diet. Many countries with low COVID-19 death rates have a common feature of eating large quantities of fermented vegetables such as cabbage and, in some continents, various spices. Fermented vegetables and spices are agonists of the antioxidant transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2), and spices are transient receptor potential ankyrin 1 and vanillin 1 (TRPA1/V1) agonists. These mechanisms may explain many COVID-19 symptoms and severity. It appears that there is a synergy between Nrf2 and TRPA1/V1 foods that may explain the role of diet in COVID-19. One of the mechanisms of COVID-19 appears to be an oxygen species (ROS)-mediated process in synergy with TRP channels, modulated by Nrf2 pathways. Spicy foods are likely to desensitize TRP channels and act in synergy with exogenous antioxidants that activate the Nrf2 pathway. © 2020

Published
2021

52. EAACI Biologicals Guidelines—Recommendations for severe asthma

Author

Agache, I. Akdis, C.A. Akdis, M. Canonica, G.W. Casale, T. Chivato, T. Corren, J. Chu, D.K. Del Giacco, S. Eiwegger, T. Flood, B. Firinu, D. Gern, J.E. Hamelmann, E. Hanania, N. Hernández-Martín, I. Knibb, R. Mäkelä, M. Nair, P. O’Mahony, L. Papadopoulos, N.G. Papi, A. Park, H.-S. Pérez de Llano, L. Pfaar, O. Quirce, S. Sastre, J. Shamji, M. Schwarze, J. Palomares, O. Jutel, M.

Abstract

Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2021

53. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus

Author

Hagemann, J. Onorato, G.L. Jutel, M. Akdis, C.A. Agache, I. Zuberbier, T. Czarlewski, W. Mullol, J. Bedbrook, A. Bachert, C. Bennoor, K.S. Bergmann, K.-C. Braido, F. Camargos, P. Caraballo, L. Cardona, V. Casale, T. Cecchi, L. Chivato, T. Chu, D.K. Cingi, C. Correia-de-Sousa, J. del Giacco, S. Dokic, D. Dykewicz, M. Ebisawa, M. El-Gamal, Y. Emuzyte, R. Fauquert, J.-L. Fiocchi, A. Fokkens, W.J. Fonseca, J.A. Gemicioglu, B. Gomez, R.-M. Gotua, M. Haahtela, T. Hamelmann, E. Iinuma, T. Ivancevich, J.C. Jassem, E. Kalayci, O. Kardas, P. Khaitov, M. Kuna, P. Kvedariene, V. Larenas-Linnemann, D.E. Lipworth, B. Makris, M. Maspero, J.F. Miculinic, N. Mihaltan, F. Mohammad, Y. Montefort, S. Morais-Almeida, M. Mösges, R. Naclerio, R. Neffen, H. Niedoszytko, M. O’Hehir, R.E. Ohta, K. Okamoto, Y. Okubo, K. Panzner, P. Papadopoulos, N.G. Passalacqua, G. Patella, V. Pereira, A. Pfaar, O. Plavec, D. Popov, T.A. Prokopakis, E.P. Puggioni, F. Raciborski, F. Reijula, J. Regateiro, F.S. Reitsma, S. Romano, A. Rosario, N. Rottem, M. Ryan, D. Samolinski, B. Sastre, J. Solé, D. Sova, M. Stellato, C. Suppli-Ulrik, C. Tsiligianni, I. Valero, A. Valiulis, A. Valovirta, E. Vasankari, T. Ventura, M.T. Wallace, D. Wang, D.Y. Williams, S. Yorgancioglu, A. Yusuf, O.M. Zernotti, M. Bousquet, J. Klimek, L.

Abstract

Background: Although there are many asymptomatic patients, one of the problems of COVID-19 is early recognition of the disease. COVID-19 symptoms are polymorphic and may include upper respiratory symptoms. However, COVID-19 symptoms may be mistaken with the common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate upper respiratory symptoms between the three diseases. Methods: A modified Delphi process was used. The ARIA members who were seeing COVID-19 patients were asked to fill in a questionnaire on the upper airway symptoms of COVID-19, common cold and allergic rhinitis. Results: Among the 192 ARIA members who were invited to respond to the questionnaire, 89 responded and 87 questionnaires were analysed. The consensus was then reported. A two-way ANOVA revealed significant differences in the symptom intensity between the three diseases (p

Published
2021

54. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Author

Pfaar, O. Klimek, L. Jutel, M. Akdis, C.A. Bousquet, J. Breiteneder, H. Chinthrajah, S. Diamant, Z. Eiwegger, T. Fokkens, W.J. Fritsch, H.-W. Nadeau, K.C. O’Hehir, R.E. O’Mahony, L. Rief, W. Sampath, V. Schedlowski, M. Torres, M.J. Traidl-Hoffmann, C. Wang, D.Y. Zhang, L. Bonini, M. Brehler, R. Brough, H.A. Chivato, T. Del Giacco, S.R. Dramburg, S. Gawlik, R. Gelincik, A. Hoffmann-Sommergruber, K. Hox, V. Knol, E.F. Lauerma, A. Matricardi, P.M. Mortz, C.G. Ollert, M. Palomares, O. Riggioni, C. Schwarze, J. Skypala, I. Untersmayr, E. Walusiak-Skorupa, J. Ansotegui, I.J. Bachert, C. Bedbrook, A. Bosnic-Anticevich, S. Brussino, L. Canonica, G.W. Cardona, V. Carreiro-Martins, P. Cruz, A.A. Czarlewski, W. Fonseca, J.A. Gotua, M. Haahtela, T. Ivancevich, J.C. Kuna, P. Kvedariene, V. Larenas-Linnemann, D.E. Abdul Latiff, A.H. Mäkelä, M. Morais-Almeida, M. Mullol, J. Naclerio, R. Ohta, K. Okamoto, Y. Onorato, G.L. Papadopoulos, N.G. Patella, V. Regateiro, F.S. Samoliński, B. Suppli Ulrik, C. Toppila-Salmi, S. Valiulis, A. Ventura, M.-T. Yorgancioglu, A. Zuberbier, T. Agache, I.

Subjects
education
Abstract

Background: The coronavirus disease 2019 (COVID-19) has evolved into a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Allergists and other healthcare providers (HCPs) in the field of allergies and associated airway diseases are on the front line, taking care of patients potentially infected with SARS-CoV-2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics. Method: The scientific information on COVID-19 was analysed by a literature search in MEDLINE, PubMed, the National and International Guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library, and the internet. Results: Based on the diagnostic and treatment standards developed by EAACI, on international information regarding COVID-19, on guidelines of the World Health Organization (WHO) and other international organizations, and on previous experience, a panel of experts including clinicians, psychologists, IT experts, and basic scientists along with EAACI and the “Allergic Rhinitis and its Impact on Asthma (ARIA)” initiative have developed recommendations for the optimal management of allergy clinics during the current COVID-19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies. Conclusions: This international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients while ensuring the necessary safety measures in the current COVID-19 pandemic. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2021

55. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Author

Agache, I, Song, Y, Alonso-Coello, P, Vogel, Y, Rocha, C, Sola, I, Santero, M, Akdis, C, Akdis, M, Canonica, GW, Chivato, T, del Giacco, S, Eiwegger, T, Fokkens, W, Georgalas, C, Gevaert, P, Hopkins, C, Klimek, L, Lund, V, Naclerio, R, O'Mahony, L, Palkonen, S, Pfaar, O, Schwarze, J, Soyka, MB, Wang, DY, Zhang, L, Canelo-Aybar, C, Palomares, O, and Jutel, M

Subjects
chronic rhinosinusitis, dupilumab, mepolizumab, omalizumab, reslizumab
Abstract

This systematic review evaluates the efficacy and safety of biologicals for chronic rhinosinusitis with nasal polyps (CRSwNP) compared with the standard of care. PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CRSwNP-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. RCTs evaluated (dupilumab-2, omalizumab-4, mepolizumab-2, and reslizumab-1) included 1236 adults, with follow-up of 20-64 weeks. Dupilumab reduces the need for surgery (NFS) or oral corticosteroid (OCS) use (RR 0.28; 95% CI 0.20-0.39, moderate certainty) and improves with high certainty smell evaluated with UPSIT score (mean difference (MD) +10.54; 95% CI +9.24 to +11.84) and quality of life (QoL) evaluated with SNOT-22 (MD -19.14; 95% CI -22.80 to -15.47), with fewer treatment-related adverse events (TAEs) (RR 0.95; 95% CI 0.89-1.02, moderate certainty). Omalizumab reduces NFS (RR 0.85; 95% CI 0.78-0.92, high certainty), decreases OCS use (RR 0.38; 95% CI 0.10-1.38, moderate certainty), and improves high certainty smell (MD +3.84; 95% CI +3.64 to +4.04) and QoL (MD -15.65; 95% CI -16.16 to -15.13), with increased TAE (RR 1.73; 95% CI 0.60-5.03, moderate certainty). There is low certainty for mepolizumab reducing NFS (RR 0.78; 95% CI 0.64-0.94) and improving QoL (MD -13.3; 95% CI -23.93 to -2.67) and smell (MD +0.7; 95% CI -0.48 to +1.88), with increased TAEs (RR 1.64; 95% CI 0.41-6.50). The evidence for reslizumab is very uncertain.

Published
2021

56. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

Author

Zuberbier, T. Dörr, T. Aberer, W. Alvaro, M. Angier, E. Arasi, S. Arshad, H. Ballmer-Weber, B. Bartra, J. Beck, L. Bégin, P. Bindslev-Jensen, C. Bislimovska, J. Bousquet, J. Brockow, K. Bush, A. Cianferoni, A. Cork, M.J. Custovic, A. Darsow, U. de Jong, N. Deleanu, D. Del Giacco, S. Deschildre, A. Dunn Galvin, A. Ebisawa, M. Fernández-Rivas, M. Ferrer, M. Fiocchi, A. Gerth van Wijk, R. Gotua, M. Grimshaw, K. Grünhagen, J. Heffler, E. Hide, M. Hoffmann-Sommergruber, K. Incorvaia, C. Janson, C. Malte John, S. Jones, C. Jutel, M. Katoh, N. Kendziora, B. Kinaciyan, T. Knol, E. Kurbacheva, O. Lau, S. Loh, R. Lombardi, C. Mäkelä, M. Marchisotto, M.J. Makris, M. Maurer, M. Meyer, R. Mijakoski, D. Minov, J. Mullol, J. Nilsson, C. Nowak–Wegrzyn, A. Nwaru, B.I. Odemyr, M. Pajno, G.B. Paudel, S. Papadopoulos, N.G. Renz, H. Ricci, G. Ring, J. Rogala, B. Sampson, H. Senna, G. Sitkauskiene, B. Smith, P.K. Stevanovic, K. Stoleski, S. Szajewska, H. Tanaka, A. Todo-Bom, A. Topal, F.A. Valovirta, E. Van Ree, R. Venter, C. Wöhrl, S. Wong, G.W.K. Zhao, Z. Worm, M.

Subjects
digestive, oral, and skin physiology
Abstract

Background: Food anaphylaxis is commonly elicited by unintentional ingestion of foods containing the allergen above the tolerance threshold level of the individual. While labeling the 14 main allergens used as ingredients in food products is mandatory in the EU, there is no legal definition of declaring potential contaminants. Precautionary allergen labeling such as “may contain traces of” is often used. However, this is unsatisfactory for consumers as they get no information if the contamination is below their personal threshold. In discussions with the food industry and technologists, it was suggested to use a voluntary declaration indicating that all declared contaminants are below a threshold of 0.5 mg protein per 100 g of food. This concentration is known to be below the threshold of most patients, and it can be technically guaranteed in most food production. However, it was also important to assess that in case of accidental ingestion of contaminants below this threshold by highly allergic patients, no fatal anaphylactic reaction could occur. Therefore, we performed a systematic review to assess whether a fatal reaction to 5mg of protein or less has been reported, assuming that a maximum portion size of 1kg of a processed food exceeds any meal and thus gives a sufficient safety margin. Methods: MEDLINE and EMBASE were searched until 24 January 2021 for provocation studies and case reports in which one of the 14 major food allergens was reported to elicit fatal or life-threatening anaphylactic reactions and assessed if these occurred below the ingestion of 5mg of protein. A Delphi process was performed to obtain an expert consensus on the results. Results: In the 210 studies included, in our search, no reports of fatal anaphylactic reactions reported below 5 mg protein ingested were identified. However, in provocation studies and case reports, severe reactions below 5 mg were reported for the following allergens: eggs, fish, lupin, milk, nuts, peanuts, soy, and sesame seeds. Conclusion: Based on the literature studied for this review, it can be stated that cross-contamination of the 14 major food allergens below 0.5 mg/100 g is likely not to endanger most food allergic patients when a standard portion of food is consumed. We propose to use the statement “this product contains the named allergens in the list of ingredients, it may contain traces of other contaminations (to be named, e.g. nut) at concentrations less than 0.5 mg per 100 g of this product” for a voluntary declaration on processed food packages. This level of avoidance of cross-contaminations can be achieved technically for most processed foods, and the statement would be a clear and helpful message to the consumers. However, it is clearly acknowledged that a voluntary declaration is only a first step to a legally binding solution. For this, further research on threshold levels is encouraged. © 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Published
2021

57. Management of anaphylaxis due to COVID-19 vaccines in the elderly

Author

Bousquet, J. Agache, I. Blain, H. Jutel, M. Ventura, M.T. Worm, M. Del Giacco, S. Benetos, A. Bilo, B.M. Czarlewski, W. Abdul Latiff, A.H. Al-Ahmad, M. Angier, E. Annesi-Maesano, I. Atanaskovic-Markovic, M. Bachert, C. Barbaud, A. Bedbrook, A. Bennoor, K.S. Berghea, E.C. Bindslev-Jensen, C. Bonini, S. Bosnic-Anticevich, S. Brockow, K. Brussino, L. Camargos, P. Canonica, G.W. Cardona, V. Carreiro-Martins, P. Carriazo, A. Casale, T. Caubet, J.-C. Cecchi, L. Cherubini, A. Christoff, G. Chu, D.K. Cruz, A.A. Dokic, D. El-Gamal, Y. Ebisawa, M. Eberlein, B. Farrell, J. Fernandez-Rivas, M. Fokkens, W.J. Fonseca, J.A. Gao, Y. Gavazzi, G. Gawlik, R. Gelincik, A. Gemicioğlu, B. Gotua, M. Guérin, O. Haahtela, T. Hoffmann-Sommergruber, K. Hoffmann, H.J. Hofmann, M. Hrubisko, M. Illario, M. Irani, C. Ispayeva, Z. Ivancevich, J.C. Julge, K. Kaidashev, I. Khaitov, M. Knol, E. Kraxner, H. Kuna, P. Kvedariene, V. Lauerma, A. Le, L.T.T. Le Moing, V. Levin, M. Louis, R. Lourenco, O. Mahler, V. Martin, F.C. Matucci, A. Milenkovic, B. Miot, S. Montella, E. Morais-Almeida, M. Mortz, C.G. Mullol, J. Namazova-Baranova, L. Neffen, H. Nekam, K. Niedoszytko, M. Odemyr, M. O’Hehir, R.E. Okamoto, Y. Ollert, M. Palomares, O. Papadopoulos, N.G. Panzner, P. Passalacqua, G. Patella, V. Petrovic, M. Pfaar, O. Pham-Thi, N. Plavec, D. Popov, T.A. Recto, M.T. Regateiro, F.S. Reynes, J. Roller-Winsberger, R.E. Rolland, Y. Romano, A. Rondon, C. Rottem, M. Rouadi, P.W. Salles, N. Samolinski, B. Santos, A.F. S Sarquis, F. Sastre, J. M. G. A. Schols, J. Scichilone, N. Sediva, A. Shamji, M.H. Sheikh, A. Skypala, I. Smolinska, S. Sokolowska, M. Sousa-Pinto, B. Sova, M. Stelmach, R. Sturm, G. Suppli Ulrik, C. Todo-Bom, A.M. Toppila-Salmi, S. Tsiligianni, I. Torres, M. Untersmayr, E. Urrutia Pereira, M. Valiulis, A. Vitte, J. Vultaggio, A. Wallace, D. Walusiak-Skorupa, J. Wang, D.-Y. Waserman, S. Yorgancioglu, A. Yusuf, O.M. Zernotti, M. Zidarn, M. Chivato, T. Akdis, C.A. Zuberbier, T. Klimek, L.

Abstract

Older adults, especially men and/or those with diabetes, hypertension, and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritized to receive COVID-19 vaccines due to high risk of death. In very rare instances, the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society) Working Group has proposed some recommendations for older adults receiving the COVID-19 vaccines. Anaphylaxis to COVID-19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients. © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2021

58. The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective

Author

Bousquet, J. Jutel, M. Pfaar, O. Fonseca, J.A. Agache, I. Czarlewski, W. Bachert, C. Bergmann, K.C. Cruz, A.A. Klimek, L. Kvedariene, V. Larenas-Linnemann, D.E. Papadopoulos, N.G. Patella, V. Regateiro, F.S. Scichilone, N. Shamji, M.H. Sheikh, A. Valovirta, E. Ventura, M.-T. Zuberbier, T.

Abstract

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology. © 2021 American Academy of Allergy, Asthma & Immunology

Published
2021

59. Biologicals in atopic disease in pregnancy: An EAACI position paper

Author

Pfaller, B. José Yepes-Nuñez, J. Agache, I. Akdis, C.A. Alsalamah, M. Bavbek, S. Bossios, A. Boyman, O. Chaker, A. Chan, S. Chatzipetrou, A. du Toit, G. Jutel, M. Kauppi, P. Kolios, A. Li, C. Matucci, A. Marson, A. Bendien, S. Palomares, O. Rogala, B. Szepfalusi, Z. Untersmayr, E. Vultaggio, A. Eiwegger, T.

Abstract

Biologicals have transformed the management of severe disease phenotypes in asthma, atopic dermatitis, and chronic spontaneous urticaria. As a result, the number of approved biologicals for the treatment of atopic diseases is continuously increasing. Although atopic diseases are among the most common diseases in the reproductive age, investigations, and information on half-life, pharmacokinetics defining the neonatal Fc receptors (FcRn) and most important safety of biologicals in pregnancy are lacking. Given the complex sequence of immunological events that regulate conception, fetal development, and the intrauterine and postnatal maturation of the immune system, this information is of utmost importance. We conducted a systematic review on biologicals in pregnancy for indications of atopic diseases. Evidence in this field is scarce and mainly reserved to reports on the usage of omalizumab. This lack of evidence demands the establishment of a multidisciplinary approach for the management of pregnant women who receive biologicals and multicenter registries for long-term follow-up, drug trial designs suitable for women in the reproductive age, and better experimental models that represent the human situation. Due to the very long half-life of biologicals, preconception counseling and healthcare provider education are crucial to offer the best care for mother and fetus. This position paper integrates available data on safety of biologicals during pregnancy in atopic diseases via a systematic review with a detailed review on immunological considerations how inhibition of different pathways may impact pregnancy. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2021

60. COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic – an EAACI/ARIA Position Paper

Author

Pfaar, O, Klimek, L, Jutel, M, Akdis, Cezmi A; https://orcid.org/0000-0001-8020-019X, et al, Pfaar, O, Klimek, L, Jutel, M, Akdis, Cezmi A; https://orcid.org/0000-0001-8020-019X, and et al

Abstract

Background The Coronavirus disease 2019 (COVID‐19) has evolved as a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS‐CoV‐)2. Allergists and other health care providers (HCPs) in the field of allergies and associated airway diseases are in the front line, taking care of patients potentially infected with SARS‐CoV‐2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics. Method The scientific information on COVID‐19 was analyzed by a literature search in Medline, Pubmed, national and international guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library and the Internet. Results Based on diagnostic and treatment standards developed by EAACI, on international information regarding COVID‐19, on guidelines of the World Health Organization (WHO) and other international organizations as well as on previous experience, a panel of experts including clinicians, psychologists, IT experts and basic scientists along with EAACI and the “Allergic Rhinitis and its Impact on Asthma (ARIA)” inititiative have developed recommendations for the optimal management of allergy clinics during the current COVID‐19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies. Conclusions This international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients whilst ensuring necessary safety in the current COVID‐19 pandemic.

Published
2021

61. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic - an EAACI/ARIA Position Paper

Author

CTI Research, CTI, MS Dermatologie/Allergologie, Infection & Immunity, Pfaar, O, Klimek, L, Jutel, M, Akdis, C A, Bousquet, J, Breiteneder, H, Chinthrajah, S, Diamant, Z, Eiwegger, T, Fokkens, W J, Fritsch, H W, Nadeau, K C, O'Hehir, R E, O'Mahony, L, Rief, W, Sampath, V, Schedlowski, M, Torres, M, Traidl-Hoffmann, C, Wang, D Y, Zhang, L, Bonini, M, Brehler, R, Brough, H A, Chivato, T, Del Giacco, S, Dramburg, S, Gawlik, R, Gelincik, A, Hoffmann-Sommergruber, K, Hox, V, Knol, E, Lauerma, A, Matricardi, P M, Mortz, C G, Ollert, M, Palomares, O, Riggioni, C, Schwarze, J, Skypala, I, Untersmayr, S, Walusiak-Skorupa, J, Ansotegui, I, Bachert, C, Bedbrook, A, Bosnic-Anticevich, S, Brussino, L, Canonica, G W, Cardona, V, Carreiro-Martins, P, Cruz, A A, Czarlewski, W, Fonseca, J A, Gotua, M, Haatela, T, Ivancevich, J C, Kuna, P, Kvedariene, V, Larenas-Linnemann, D, Latiff, A, Morais-Almeida, M, Mullol, J, Naclerio, R, Ohta, K, Okamoto, Y, Onorato, G L, Papadopoulos, N G, Patella, V, Regateiro, F S, Samolinski, B, Suppli Ulrik, C, Toppila-Salmi, S, Valiulis, A, Ventura, M T, Yorgancioglu, A, Zuberbier, T, Agache, I, CTI Research, CTI, MS Dermatologie/Allergologie, Infection & Immunity, Pfaar, O, Klimek, L, Jutel, M, Akdis, C A, Bousquet, J, Breiteneder, H, Chinthrajah, S, Diamant, Z, Eiwegger, T, Fokkens, W J, Fritsch, H W, Nadeau, K C, O'Hehir, R E, O'Mahony, L, Rief, W, Sampath, V, Schedlowski, M, Torres, M, Traidl-Hoffmann, C, Wang, D Y, Zhang, L, Bonini, M, Brehler, R, Brough, H A, Chivato, T, Del Giacco, S, Dramburg, S, Gawlik, R, Gelincik, A, Hoffmann-Sommergruber, K, Hox, V, Knol, E, Lauerma, A, Matricardi, P M, Mortz, C G, Ollert, M, Palomares, O, Riggioni, C, Schwarze, J, Skypala, I, Untersmayr, S, Walusiak-Skorupa, J, Ansotegui, I, Bachert, C, Bedbrook, A, Bosnic-Anticevich, S, Brussino, L, Canonica, G W, Cardona, V, Carreiro-Martins, P, Cruz, A A, Czarlewski, W, Fonseca, J A, Gotua, M, Haatela, T, Ivancevich, J C, Kuna, P, Kvedariene, V, Larenas-Linnemann, D, Latiff, A, Morais-Almeida, M, Mullol, J, Naclerio, R, Ohta, K, Okamoto, Y, Onorato, G L, Papadopoulos, N G, Patella, V, Regateiro, F S, Samolinski, B, Suppli Ulrik, C, Toppila-Salmi, S, Valiulis, A, Ventura, M T, Yorgancioglu, A, Zuberbier, T, and Agache, I

Published
2021

64. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology

Author

Muraro, A., Roberts, G., Worm, M., Bilò, M. B., Brockow, K., Rivas, Fernández M., Santos, A. F., Zolkipli, Z. Q., Bellou, A., Beyer, K., Bindslev-Jensen, C., Cardona, V., Clark, A. T., Demoly, P., Dubois, A. E. J., DunnGalvin, A., Eigenmann, P., Halken, S., Harada, L., Lack, G., Jutel, M., Niggemann, B., Ruëff, F., Timmermans, F., Vlieg–Boerstra, B. J., Werfel, T., Dhami, S., Panesar, S., Akdis, C. A., and Sheikh, A.

Published
2014
Full Text
View/download PDF

67. Is diet partly responsible for differences in COVID-19 death rates between and within countries? (vol 10, 16, 2020)

Author

Bousquet, J, Anto, JM, Iaccarino, G, Czarlewski, W, Haahtela, T, Anto, A, Akdis, CA, Blain, H, Canonica, GW, Cardona, V, Cruz, AA, Illario, M, Ivancevich, JC, Jutel, M, Klimek, L, Kuna, P, Laune, D, Larenas-Linnemann, D, Mullol, J, Papadopoulos, NG, Pfaar, O, Samolinski, B, Valiulis, A, Yorgancioglu, A, and Zuberbier, T

Subjects
Science & Technology, ARIA group, Allergy, Life Sciences & Biomedicine
Published
2020

68. Allergen-Immuntherapie in der aktuellen COVID-19-Pandemie : Ein Positionspapier von ARIA, EAACI, AeDA, GPA und DGAKI (Kurzversion)

Author

Pfaar, O., Klimek, L., Worm, M., Bergmann, K.-C., Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., Maurer, M., Merk, H., Mösges, R., Saloga, J., Staubach, P., Stute, P., Rabe, K., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Mülleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P.-V., Aberer, W., Fink-Wagner, A., Horak, F., Wöhrl, S., Niederberger-Leppin, V., Pali-Schöll, I., Pohl, W., Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Akdis, C., Hoffmann-Sommergruber, K., Jutel, M., Matricardi, P., Spertini, F., Khaltaev, N., Michel, J.-P., Nicod, L., Schmid-Grendelmeier, P., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, Christian, Gerstlauer, M., Vogelberg, C., Bousquet, J., and Zuberbier, T.

Subjects
Betacoronavirus, Desensitization, Immunologic, SARS-CoV-2, Pneumonia, Viral, Medizin, COVID-19, Humans, Coronavirus Infections, Pandemics
Published
2020

69. Efficacy and safety of treatment with dupilumab for severe asthma : A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma

Author

Agache, I, Song, Y, Rocha, C, Beltran, J, Posso, M, Steiner, C, Alonso-Coello, P, Akdis, C, Akdis, M, Canonica, GW, Casale, T, Chivato, T, Corren, J, del Giacco, S, Eiwegger, T, Firinu, D, Gern, JE, Hamelmann, E, Hanania, N, Makela, M, Martin, IH, Nair, P, O'Mahony, L, Papadopoulos, NG, Papi, A, Park, HS, de Llano, LP, Quirce, S, Sastre, J, Shamji, M, Schwarze, J, Canelo-Aybar, C, Palomares, O, Jutel, M, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, and Helsinki University Hospital Area

Subjects
severe asthma, INFORMATION, oral corticosteroids, WILLINGNESS-TO-PAY, EURONHEED, GRADE, exacerbations, ECONOMIC EVALUATIONS, dupilumab, 3121 General medicine, internal medicine and other clinical medicine, QUALITY, FENO, BURDEN, CONSENSUS, cost-effectiveness, SURROGATES
Abstract

Dupilumab, a fully human monoclonal antibody against interleukin-4 receptor alpha, is approved as add-on maintenance treatment for inadequately controlled type 2 severe asthma. This systematic review evaluated the efficacy, safety and economic impact of dupilumab compared to standard of care for uncontrolled severe asthma. PubMed, EMBASE and Cochrane Library were searched for RCTs and health economic evaluations. Critical and important asthma-related outcomes were evaluated. The risk of bias and the certainty of the evidence were assessed using GRADE. Three RCTs including 2735 subjects >12 years old and 24-52 weeks of follow-up were included. Dupilumab reduced with high certainty severe asthma exacerbations (Incidence rate ratio 0.51; 95% CI 0.45-0.59) and the percentage use of oral corticosteroid use (mean difference (MD) -28.2 mg/d; 95% CI -40.7 to -15.7). Asthma control (ACQ-5), quality of life (AQLQ) and rescue medication use [puffs/d] improved, without reaching the minimal important clinical difference: ACQ-5 MD -0.28 (95% CI -0.39 to -0.17); AQLQ MD +0.28 (95% CI 0.20-0.37); and rescue medication MD -0.35 (95% CI -0.73 to +0.02). FEV1 increased (MD +0.15; 95% CI +0.11 to +0.18) (moderate certainty). There was an increased rate of dupilumab-related adverse events (AEs) (moderate certainty) and of drug-related serious AEs (low certainty). The incremental cost-effectiveness ratio of dupilumab versus standard therapy was 464 000$/QALY (moderate certainty). More data on long-term safety are needed both for children and for adults, together with more efficacy data in the paediatric population.

Published
2020

70. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

Author

Bousquet, J. Akdis, C.A. Jutel, M. Bachert, C. Klimek, L. Agache, I. Ansotegui, I.J. Bedbrook, A. Bosnic-Anticevich, S. Canonica, G.W. Chivato, T. Cruz, A.A. Czarlewski, W. Del Giacco, S. Du, H. Fonseca, J.A. Gao, Y. Haahtela, T. Hoffmann-Sommergruber, K. Ivancevich, J.-C. Khaltaev, N. Knol, E.F. Kuna, P. Larenas-Linnemann, D. Mullol, J. Naclerio, R. Ohta, K. Okamoto, Y. O’Mahony, L. Onorato, G.L. Papadopoulos, N.G. Pfaar, O. Samolinski, B. Schwarze, J. Toppila-Salmi, S. Ventura, M.-T. Valiulis, A. Yorgancioglu, A. Zuberbier, T. Pawankar, R. Mubeccel, A. Mona, A.-A. Emilio, A.C. Hasan, A. Cristina, A.M. Zeinab, A. Mostafa, B.E. Sergio, B. Cristina, B. Eric, B. Bianca, B. Elisabeth, B. Larl-Christian, B. David, B. Leif, B. Attilio, B. Sergio, B. isabelle, B. Jacques, B. Louis-Philippe, B. Fulvio, B. Christopher, B. Roland, B. Carmen, B. Andrew, B. William, B. Fernan, C.-F. Davide, C. Silvia, C. Paulo, C. Walter, C. Vicky, C. Kai-Hakon, C. Warner, C. Thomas, C. Lorenzo, C. Alfonso, C.M. Niels, C. Ekaterine, C. George, C. Derek, C. Cemal, C. Giorgio, C. Ieva, C. Sousa Jaime, C.D. Maria del Carmen, C.D. André, C. Linda, C. Alvaro, C. Adnan, C. Ulf, D. Frédéric, D.B. Diana, D. Pascal, D. Philippe, D. Alain, D. Ratko, D. Maria, D.C.T. Dejan, D. Ruta, D. Stephen, D. Patrik, E. Yehia, E.-G. Regina, E. Bieren Julia, E.-V. Alessandro, F. Wytske, F. Mina, G. Luis, G.R.J. Bilun, G. Sonya, G. José, G. Maximiliano, G. Maia, G. Ineta, G. Marta, G. Antonieta, G.M. Adnan, H. Elham, H. Jonathan, H. Martin, H. Yunuen, H.V. Guido, I. Carla, I. Zhanat, I. Edgardo, J. Ewa, J. Erika, J.-J. Sebastian, J. Guy, J. Ki-Suck, J. Jocelyne, J. Igor, K. Omer, K. Fuat, K. Przemyslaw, K. Jussi, K. Jorg, K.-T. Gerard, K. Marek, K. Mikael, K. Violeta, K. Amir, L. Susanne, L. Lan, L. Marcus, L. Michael, L. Jing, L. Philip, L. Brian, L. Karin, L.C. Bassam, M. Mika, M. Hans-Jorgen, M. Gailen, M. Pedro, M. Mohammad, M. Juan-José, M. Cem, M. Erik, M. Eli, M. Hans, M. Jean-Pierre, M. Florin, M. Neven, M. Branislava, M. Yousser, M. Mathieu, M. Mario, M.-A. Ralph, M. Lars, M. Antonella, M. Tihomir, M. Alla, N. Leyla, N.-B. Kristof, N. Laurent, N. Robyn, O. Kimihiro, O. Brian, O. Luigi, P.P. Isabella, P.-S. Petr, P. Nilos, P. Sim, P.H. Ruby, P. Ana, P. Bernard, P. Constantinos, P. Davor, P. Wolfgang, P. Todor, P. Fabienne, P. Paul, P. Lars, P. Emmanuel, P. Claus, R. Stella, R.M. Janet, R. José Angelo, R. Graham, R. Nicolas, R. Antonino, R. Jose, R.-P. Nelson, R. Lanny, R. Philip, R. Dermot, R. Mario, S.-B. Joaquin, S.-D. Glenis, S. Elie, S. Nikolaos, S. Estelle, S. Juan-Carlos, S. Dirceu, S. Talant, S. Manuel, S.-M. Cristiana, S. Rafael, S. Timo, S. Charlotte, S.U. Carel, T. Peter-Valentin, T. Massimo, T. Ioana, T. Marilyn, U.P. Erkka, V. Eric, V.G. Marianne, V.H. Olivier, V. Petra, V. Martin, W. Dana, W. Yun, W.D. Susan, W. Magnus, W. Dennis, W. Barbara, Y. Arzu, Y. Osman, Y. Mario, Z. Mihaela, Z. the ARIA-MASK Study Group

Published
2020

71. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Author

Agache, I. Rocha, C. Beltran, J. Song, Y. Posso, M. Solà, I. Alonso-Coello, P. Akdis, C. Akdis, M. Canonica, G.W. Casale, T. Chivato, T. Corren, J. Del Giacco, S. Eiwegger, T. Firinu, D. Gern, J.E. Hamelmann, E. Hanania, N. Mäkelä, M. Martín, I.H. Nair, P. O'Mahony, L. Papadopoulos, N.G. Papi, A. Park, H.-S. Pérez de Llano, L. Quirce, S. Sastre, J. Shamji, M. Schwarze, J. Canelo-Aybar, C. Palomares, O. Jutel, M.

Abstract

Allergic asthma is a frequent asthma phenotype. Both IgE and type 2 cytokines are increased, with some degree of overlap with other phenotypes. Systematic reviews assessed the efficacy and safety of benralizumab, dupilumab and omalizumab (alphabetical order) vs standard of care for patients with uncontrolled severe allergic asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma-related outcomes were evaluated. The risk of bias and the certainty of the evidence were assessed using GRADE. All three biologicals reduced with high certainty the annualized asthma exacerbation rate: benralizumab incidence rate ratios (IRR) 0.63 (95% CI 0.50 − 0.81); dupilumab IRR 0.58 (95%CI 0.47 − 0.73); and omalizumab IRR 0.56 (95%CI 0.42 − 0.73). Benralizumab and dupilumab improved asthma control with high certainty and omalizumab with moderate certainty; however, none reached the minimal important difference (MID). Both benralizumab and omalizumab improved QoL with high certainty, but only omalizumab reached the MID. Omalizumab enabled ICS dose reduction with high certainty. Benralizumab and omalizumab showed an increase in drug-related adverse events (AEs) with low to moderate certainty. All three biologicals had moderate certainty for an ICER/QALY value above the willingness to pay threshold. There was high certainty that in children 6-12 years old omalizumab decreased the annualized exacerbation rate [IRR 0.57 (95%CI 0.45-0.72)], improved QoL [relative risk 1.43 (95%CI 1.12 −1.83)], reduced ICS [mean difference (MD) −0.45 (95% CI −0.58 to −0.32)] and rescue medication use [MD −0.41 (95%CI −0.66 to −0.15)]. © 2020 John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2020

72. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B<

Author

Klimek, L., Pfaar, O., Worm, M., Eiwegger, T., Hagemann, J., Ollert, M., Untersmayr, E., Hoffmann-Sommergruber, K., Vultaggio, A., Agache, I., Bavbek, S., Bossios, A., Casper, I., Chan, S., Chatzipetrou, A., Vogelberg, C., Firinu, D., Kauppi, P., Kolios, A., Kothari, A., Matucci, A., Palomares, O., Szépfalusi, Z., Pohl, W., Hötzenecker, W., Rosenkranz, A.R., Bergmann, K.C., Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., Maurer, M., Merk, H., Mösges, R., Saloga, J., Staubach, P., Jappe, U., Rabe, K.F., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Freudelsperger, L., Mülleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P.V., Aberer, W., Fink-Wagner, A.H., Horak, F., Wöhrl, S., Niederberger-Leppin, V., Pali-Schöll, I., Roller-Wirnsberger, R., Spranger, O., Akdis, M., Matricardi, P.M., Spertini, F., Khaltaev, N., Michel, J.P., Nicod, L., Schmid-Grendelmeier, P., Idzko, M., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Jensen-Jarolim, E., Korn, S., Hentges, F., Schwarze, J., O Mahony, L., Knol, E.F., Del Giacco, S., Chivato Pérez, T., Bedbrook, A., Zuberbier, T., Akdis, C., and Jutel, M.

Subjects
Covid-19, Sars-cov-2, Benralizumab, Dupilumab, Mepolizumab, Omalizumab, Reslizumab, Telemedicine
Abstract

BACKGROUND: Since the beginning of the COVID-19 pandemic, the treatment of patients with allergic and atopy-associated diseases has faced major challenges. Recommendations for "social distancing" and the fear of patients becoming infected during a visit to a medical facility have led to a drastic decrease in personal doctor-patient contacts. This affects both acute care and treatment of the chronically ill. The immune response after SARS-CoV-2 infection is so far only insufficiently understood and could be altered in a favorable or unfavorable way by therapy with monoclonal antibodies. There is currently no evidence for an increased risk of a severe COVID-19 course in allergic patients. Many patients are under ongoing therapy with biologicals that inhibit type 2 immune responses via various mechanisms. There is uncertainty about possible immunological interactions and potential risks of these biologicals in the case of an infection with SARS-CoV-2. MATERIALS AND METHODS: A selective literature search was carried out in PubMed, Livivo, and the internet to cover the past 10 years (May 2010 - April 2020). Additionally, the current German-language publications were analyzed. Based on these data, the present position paper provides recommendations for the biological treatment of patients with allergic and atopy-associated diseases during the COVID-19 pandemic. RESULTS: In order to maintain in-office consultation services, a safe treatment environment must be created that is adapted to the pandemic situation. To date, there is a lack of reliable study data on the care for patients with complex respiratory, atopic, and allergic diseases in times of an imminent infection risk from SARS-CoV-2. Type-2-dominant immune reactions, as they are frequently seen in allergic patients, could influence various phases of COVID-19, e.g., by slowing down the immune reactions. Theoretically, this could have an unfavorable effect in the early phase of a SARS-Cov-2 infection, but also a positive effect during a cytokine storm in the later phase of severe courses. However, since there is currently no evidence for this, all data from patients treated with a biological directed against type 2 immune reactions who develop COVID-19 should be collected in registries, and their disease courses documented in order to be able to provide experience-based instructions in the future. CONCLUSION: The use of biologicals for the treatment of bronchial asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and spontaneous urticaria should be continued as usual in patients without suspected infection or proven SARS-CoV-2 infection. If available, it is recommended to prefer a formulation for self-application and to offer telemedical monitoring. Treatment should aim at the best possible control of difficult-to-control allergic and atopic diseases using adequate rescue and add-on therapy and should avoid the need for systemic glucocorticosteroids. If SARS-CoV-2 infection is proven or reasonably suspected, the therapy should be determined by weighing the benefits and risks individually for the patient in question, and the patient should be involved in the decision-making. It should be kept in mind that the potential effects of biologicals on the immune response in COVID-19 are currently not known. Telemedical offers are particularly desirable for the acute consultation needs of suitable patients.

Published
2020

73. ARIA-EAACI Statement on Asthma and COVID-19

Author

Bousquet J, Jutel M, Akdis CA, Klimek L, Pfaar O, Nadeau KC, Eiwegger T, Bedbrook A, Ansotegui IJ, Anto JM, Bachert C, Bateman ED, Bennoor KS, Berghea EC, Bergmann KC, Blain H, Bonini M, Bosnic-Anticevich S, Boulet LP, Brussino L, Buhl R, Camargos P, Canonica GW, Viegi G, Zernotti M, Zidarn M, Zuberbier T, and Agache I

Subjects
COVID19, asthma
Published
2020
Full Text
View/download PDF

74. ARIA Guideline 2019: Treatment of allergic rhinitis in the German health system [ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem]

Author

Klimek, L. Bachert, C. Pfaar, O. Becker, S. Bieber, T. Brehler, R. Buhl, R. Casper, I. Chaker, A. Czech, W. Fischer, J. Fuchs, T. Gerstlauer, M. Hörmann, K. Jakob, T. Jung, K. Kopp, M.V. Mahler, V. Merk, H. Mülleneisen, N. Nemat, K. Rabe, U. Ring, J. Saloga, J. Schlenter, W. Schmidt-Weber, C. Seyfarth, H. Sperl, A. Spindler, T. Staubach, P. Strieth, S. Treudler, R. Vogelberg, C. Wallrafen, A. Wehrmann, W. Wrede, H. Zuberbier, T. Bedbrook, A. Canonica, G.W. Cardona, V. Casale, T.B. Czarlewski, W. Fokkens, W.J. Hamelmann, E. Hellings, P.W. Jutel, M. Larenas-Linnemann, D. Mullol, J. Papadopoulos, N.G. Toppila-Salmi, S. Werfel, T. Bousquet, J.

Published
2020

75. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

Author

Bousquet, J. and Farrell, J. and Onorato, G.L. and Bedbrook, A. and Czarlewski, W. and Micheli, Y. and Arnavielhe, S. and Illario, M. and Ansotegui, I.J. and Anto, J.M. and Bachert, C. and Basagaña, X. and Bédard, A. and Benveniste, S. and Bergmann, K.C. and Bewick, M. and Bindslev-Jensen, C. and Bjermer, L. and Blain, H. and Bosnic-Anticevich, S. and Bosse, I. and Braido, F. and Brussino, L. and Camuzat, T. and Canonica, G.W. and Cardona, V. and Carreiro Martins, P. and Cecchi, L. and Chavannes, N.H. and Chu, D.K. and Correia da Sousa, J. and Costa, D.J. and Costa, E. and Cruz, A.A. and da Silva, J. and Devillier, P. and de Feo, G. and de Vries, G. and Dray, G. and Ebisawa, M. and Erhola, M. and Fauquert, J.L. and Fokkens, W.J. and Fonseca, J. and Fontaine, J.M. and Gemicioğlu, B. and Haahtela, T. and Heffler, E. and Hellings, P.W. and Ivancevich, J.C. and Jassem, E. and Jutel, M. and Kaidashev, I. and Kalayci, O. and Klimek, L. and Kowalski, M.L. and Kull, I. and Kuna, P. and Kvedariene, V. and la Grutta, S. and Laune, D. and Larenas-Linnemann, D. and Ierodiakonou, D. and Le, L.T.T. and Lourenço, O. and Makris, M. and Menditto, E. and Monti, R. and Morais-Almeida, M. and Münter, L. and Muraro, A. and Murray, R. and Maurer, M. and Melén, E. and Mösges, R. and Mullol, J. and Niedoszytko, M. and O'Hehir, R.E. and Okamoto, Y. and Papadopoulos, N.G. and Passalacqua, G. and Patella, V. and Pereira, A.M. and Pfaar, O. and Pham-Thi, N. and Portejoie, F. and Price, D. and Prokopakis, E.P. and Psarros, F. and Raciborski, F. and Regateiro, F. and Reitsma, S. and Roche, N. and Rolland, C. and Ryan, D. and Samolinski, B. and Sastre, J. and Scadding, G.K. and Schmid-Grendelmeier, P. and Schünemann, H.J. and Shamji, M. and Sheikh, A. and Stellato, C. and Suppli-Ulrik, C. and Somekh, D. and Sova, M. and Todo Bom, A. and Tomazic, P.V. and Toppila-Salmi, S. and Triggiani, M. and Tsiligianni, I. and Valero, A. and Valiulis, A. and Valovirta, E. and van Eerd, M. and Vasankari, T. and Ventura, M.T. and Wallace, D. and Waserman, S. and Yorgancioglu, A. and Zidarn, M. and Zuberbier, T., CHU Arnaud de Villeneuve, Montpellier, France, MACVIA-France, Montpellier, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, France, Euforea, Brussels, Belgium, Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany, LANUA International Healthcare Consultancy, Belfast, Northern Ireland, United Kingdom, Medical Consulting Czarlewski, Levallois, France, KYomed INNOV, Montpellier, France, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D Unit and Department of Public Health), Naples, Italy, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Hospital del Mar Research Institute (IMIM), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Upper Airways Research Laboratory, Department of ENT, Ghent University Hospital, Ghent, Belgium, National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France, Mines ParisTech CRI - PSL Research University, Fontainebleau, France, iQ4U Consultants Ltd, London, United Kingdom, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Department of Respiratory Medicine and Allergology, Lund University, Lund, Sweden, Department of Geriatrics, Montpellier University Hospital, Montpellier, France, EA 2991, Euromov, University, Montpellier, France, Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, Australia, La Rochelle, France, University of Genoa, Department of Internal Medicine, DiMI) and IRCCS Ospedale Policlinico San Martino, Genova, Italy, Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino, Mauriziano Hospital, Torino, Italy, Région Occitanie, Montpellier, France, Personalized Medicine Clinic Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano (MI), Italy, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron and ARADyAL Research Network, Barcelona, Spain, Serviço de Imunoalergologia, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisbon, Portugal, CEDOC-CHRC, Faculdade de Ciências Médicas (FCM), Universidade Nova de Lisboa, Lisbon, Portugal, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada, Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Canada, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal, Nîmes, France, UCIBIO, REQUIMTE, Faculty of Pharmacy, and Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), University of Porto, Porto, Portugal, ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil, WHO GARD Planning Group, Salvador, Brazil, Allergy Service, University Hospital of Federal University of Santa Catarina (HU-UFSC), Florianópolis, Brazil, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, Peercode BV, Geldermalsen, Netherlands, IMT Mines Alès, Université Montpellier, France, Clinical Reserch Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, National Insitute for Health and Welfare, Helsinki, Finland, CHU Clermont-Ferrand, Unité d'allergologie de l'enfant, Pôle pédiatrique, Hôpital Estaing, Clermont-Ferrand, France, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda, Porto, Portugal, Reims, France, Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istambul, Turkey, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland, Department of Clinical Immunology, Wrocław Medical University, Poland, Ukrainina Medical Stomatological Academy, Poltava, Ukraine, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Poland, Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland, Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Institute of Clinical Medicine, Clinic of Chest diseases and Allergology, Faculty of Medicine, Vilnius, Lithuania, Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), Palermo, Italy, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Department of Social Medicine, Faculty of Medicine, University of Crete, International Primary Care Respiratory Group, Crete, Greece, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam, Faculty of Health Sciences and CICS - UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Allergy Unit 'D Kalogeromitros', 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece, CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Danish Commitee for Health Education, Copenhagen East, Denmark, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, MedScript, Paraparaumu, New Zealand, Optimum Patient Care, Cambridge, United Kingdom, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Germany and CRI-Clinical Research International-Ltd, Hamburg, Germany, Rhinology Unit and Smell Clinic, Department of ENT, Hospital Clínic, Barcelona, Spain, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia, Department of Immunology, Monash University, Melbourne, Australia, Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Department of Allergy, 2nd Pediatric Clinic, Athens General Children's Hospital 'P&A Kyriakou,', University of Athens, Athens, Greece, Allergy and Respiratory Diseases, Ospedale Policlino San Martino, University of Genoa, Italy, Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, Santa Maria della Speranza Hospital, Salerno, Italy, Allergy Unit, CUF-Porto Hospital and Institute, Porto, Portugal, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Germany, Department of Allergy, Pasteur Institute, Paris, France, Observational and Pragmatic Research Institute, Singapore, Singapore, Department of Otorhinolaryngology, University of Crete, School of Medicine, Heraklion, Greece, Allergy Department, Athens Naval Hospital, Athens, Greece, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Portugal, Pneumologie et Soins Intensifs Respiratoires, Hôpitaux Universitaires Paris, Centre Hôpital Cochin, Paris, France, Association Asthme et Allergie, Paris, France, Allergy and Respiratory Research Group, University of Edinburgh, Edinburgh, United Kingdom, Faculty of Medicine, Autnonous University of Madrid, Spain, Royal National TNE Hospital, University College London, London, United Kingdom, Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zürich, Switzerland, Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Imperial College London, London, United Kingdom, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Department of Respiratory Medicine, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark, European Health Futures Forum (EHFF), Dromahair, Ireland, Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of General ORL, H1NS, Medical University of Graz, Graz, Austria, Vilnius University Faculty of Medicine, Institute of Clinical Medicine, Institute of Health Sciences, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo Allergy Clinic, Turku, Finland, FILHA, Finnish Lung Association, Helsinki, Finland, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, Nova Southeastern University, Fort Lauderdale, FL, United States, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, and University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia

Abstract

The reference sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) were renewed in 2019. The DG Santé good practice Mobile Airways Sentinel networK was reviewed to meet the objectives of the EIP on AHA. It included 1) Management of care process, 2) Blueprint of digital transformation, 3) EIP on AHA, innovation to market, 4) Community for monitoring and assessment framework, 5) Political, organizational, technological and financial readiness, 6) Contributing to European co-operation and transferability, 7) Delivering evidence of impact against the triple win approach, 8) Contribution to the European Digital Transformation of Health and Care and 9) scale of demonstration and deployment of innovation. © 2020 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published
2020

76. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

Author

Vultaggio, A. Agache, I. Akdis, C.A. Akdis, M. Bavbek, S. Bossios, A. Bousquet, J. Boyman, O. Chaker, A.M. Chan, S. Chatzipetrou, A. Feleszko, W. Firinu, D. Jutel, M. Kauppi, P. Klimek, L. Kolios, A. Kothari, A. Kowalski, M.L. Matucci, A. Palomares, O. Pfaar, O. Rogala, B. Untersmayr, E. Eiwegger, T.

Abstract

The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant number of the patients are on treatment with biologicals, and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a “cytokine storm” and associated organ damage characterized by an exaggerated release of pro-inflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti-inflammatory cytokines and type 2 responses. This expert-based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID-19. Studies focusing on severe allergic phenotypes are lacking. At present, noninfected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be re-initiated. Maintenance of add-on therapy and a constant assessment of disease control, apart from acute management, are demanded. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2020

77. Correction to: 'ARIA guideline 2019: treatment of allergic rhinitis in the German health system' (Allergo Journal International, (2019), 28, 7, (255-276), 10.1007/s40629-019-00110-9)

Author

Klimek, L. Bachert, C. Pfaar, O. Becker, S. Bieber, T. Brehler, R. Buhl, R. Casper, I. Chaker, A. Czech, W. Fischer, J. Fuchs, T. Gerstlauer, M. Hörmann, K. Jakob, T. Jung, K. Kopp, M.V. Mahler, V. Merk, H. Mülleneisen, N. Nemat, K. Rabe, U. Ring, J. Saloga, J. Schlenter, W. Schmidt-Weber, C. Seyfarth, H. Sperl, A. Spindler, T. Staubach, P. Strieth, S. Treudler, R. Vogelberg, C. Wallrafen, A. Wehrmann, W. Wrede, H. Zuberbier, T. Bedbrook, A. Canonica, G.W. Cardona, V. Casale, T.B. Czarlewski, W. Fokkens, W.J. Hamelmann, E. Hellings, P.W. Jutel, M. Larenas-Linnemann, D. Mullol, J. Papadopoulos, N.G. Toppila-Salmi, S. Werfel, T. Bousquet, J.

Abstract

Correction to: Allergo J Int 2019 https://doi.org/10.1007/s40629-019-00110-9 Affiliation and disclaimer have been misrepresented and are hereby corrected: Vera Mahler: Affiliation: Med. Faculty, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Germany. Disclaimer: The views expressed in this. © 2020, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Published
2020

78. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

Author

Bousquet, J., Anto, J. M., Iaccarino, G., Czarlewski, W., Haahtela, T., Anto, A., Akdis, C. A., Blain, H., Canonica, G. W., Cardona, V., Cruz, A. A., Illario, M., Ivancevich, J. C., Jutel, M., Klimek, L., Kuna, P., Laune, D., Larenas-linnemann, D., Mullol, J., Papadopoulos, N. G., Pfaar, O., Samolinski, B., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Latiff, A. H. A., Abdullah, B., Aberer, W., Abusada, N., Adcock, I., Afani, A., Agache, I., Aggelidis, X., Agustin, J., Akdis, C., Akdis, M., Al-Ahmad, M., Bassam, A. A. -Z., Aldrey-Palacios, O., Cuesta, E. A., Alzaabi, A., Amad, S., Ambrocio, G., Annesi-Maesano, I., Ansotegui, I., Anto, J., Arshad, H., Artesani, M. C., Asayag, E., Avolio, F., Azhari, K., Baiardini, I., Bajrovic, N., Bakakos, P., Mongono, S. B., Balotro-Torres, C., Barba, S., Barbara, C., Barbosa, E., Barreto, B., Bartra, J., Bateman, E. D., Battur, L., Bedbrook, A., Barajas, M. B., Beghe, B., Bel, E., Kheder, A. B., Benson, M., Berghea, C., Bergmann, K. -C., Bernstein, D., Bewick, M., Bialek, S., Bialoszewski, A., Bieber, T., Billo, N., Bilo, M. B., Bindslev-Jensen, C., Bjermer, L., Marciniak, M. B., Bond, C., Boner, A., Bonini, M., Bonini, S., Bosnic-Anticevich, S., Bosse, I., Botskariova, S., Bouchard, J., Boulet, L. -P., Bourret, R., Bousquet, P., Braido, F., Briggs, A., Brightling, C., Brozek, J., Buhl, R., Bumbacea, R., Cabanas, M. T. B., Bush, A., Busse, W. W., Buters, J., Caballero-Fonseca, F., Calderon, M. A., Calvo, M., Camargos, P., Camuzat, T., Cano, A., Capriles-Hulett, A., Caraballo, L., Carlsen, K. -H., Caro, J., Carr, W., Carreon-Asun-cion, F., Carriazo, A. M., Casale, T., Castor, M. A., Castro, E., Cecchi, L., Sarabia, A. C., Chandrasekharan, R., Chang, Y. -S., Chato-Andeza, V., Chatzi, L., Chatzidaki, C., Chavannes, N. H., Chen, Y., Cheng, L., Chivato, T., Chkhartishvili, E., Christoff, G., Chrystyn, H., Chu, D. K., Chua, A., Chuchalin, A., Chung, K. F., Ciceran, A., Cingi, C., Ciprandi, G., Cirule, I., Coelho, A. C., Constantinidis, J., Sousa, J. C., Costa, E., Costa, D., Dominguez, M. C. C., Coste, A., Cox, L., Cullen, J., Custovic, A., Cvetkovski, B., D'Amato, G., Silva, J. D., Dahl, R., Dahlen, S. -E., Daniilidis, V., Nahhas, L. D., Darsow, U., Blay, F., Guia, E. D., Santos, C., Keenoy, E. D. M., Vries, G. D., Deleanu, D., Demoly, P., Denburg, J., Devillier, P., Didier, A., Dimou, M., Dinh-Xuan, A. T., Djukanovic, R., Dokic, D., Silva, M. G. D., Douagui, H., Douladiris, N., Doulaptsi, M., Dray, G., Dubakiene, R., Durham, S., Dykewicz, M., Ebo, D., Edelbaher, N., Eklund, P., El-Gamal, Y., El-Sayed, Z. A., El-Sayed, S. S., El-Seify, M., Emuzyte, R., Enecilla, L., Espinoza, H., Farrell, J., Fernandez, L., Wagner, A. F., Fiocchi, A., Fokkens, W. J., Fontaine, J. -F., Forastiere, F., Fuentes, J. M., Gaerlan-resureccion, E., Gaga, M., Romero, J. L. G., Gamkrelidze, A., Garcia, A., Cobas, C. Y. G., Gayraud, J., Gemicioglu, B., Genova, S., Gereda, J., Wijk, R. G., Gomez, M., Diaz, S. G., Gotua, M., Grigoreas, C., Grisle, I., Guidacci, M., Guldemond, N., Gutter, Z., Guzman, A., Halloum, R., Hamelmann, E., Hammadi, S., Harvey, R., Heinrich, J., Hejjaoui, A., Hellquist-Dahl, B., Velazquez, L. H., Hew, M., Hossny, E., Howarth, P., Hrubisko, M., Villalobos, Y. R. H., Humbert, M., Hyland, M., Ibrahim, M., Ilyina, N., Irani, C., Ispayeva, Z., Jares, E., Jarvis, D., Jassem, E., Jenko, K., Uscanga, R. D. J., Johnston, S., Joos, G., Jost, M., Julge, K., Jung, K. -S., Just, J., Kaidashev, I., Kalayci, O., Kalyoncu, F., Kapsali, J., Kardas, P., Karjalainen, J., Kasala, C. A., Katotomichelakis, M., Kazi, B., Keil, T., Keith, P., Khaitov, M., Khaltaev, N., Kim, Y. -Y., Kleine-Tebbe, J., Koffi N'Goran, B., Kompoti, E., Kopac, P., Koppelman, G., Jeverica, A. K., Kosnik, M., Kostov, K. V., Kowalski, M. L., Kralimarkova, T., Vrscaj, K. K., Kraxner, H., Kreft, S., Kritikos, V., Kudlay, D., Kull, I., Kupczyk, M., Kvedariene, V., Kyriakakou, M., Lalek, N., Lane, S., Larenas-Linnemann, D., Latiff, A., Lau, S., Lavrut, J., Le, L., Lessa, M., Levin, M., Li, J., Lieberman, P., Liotta, G., Lipworth, B., Liu, X., Lobo, R., Lodrup Carlsen, K. C., Lombardi, C., Louis, R., Loukidis, S., Lourenco, O., Luna Pech, J. A., Madjar, B., Magnan, A., Mahboub, B., Mair, A., Mais, Y., van der Zee, A. -H. M., Makela, M., Makris, M., Malling, H. -J., Mandajieva, M., Manning, P., Manousakis, M., Maragoudakis, P., Marshall, G., Martins, P., Masjedi, M. R., Maspero, J. F., Campos, J. J. M., Maurer, M., Mavale-Manuel, S., Meco, C., Melen, E., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Menzies-Gow, A., Merk, H., Michel, J. -P., Miculinic, N., Midao, L., Mihaltan, F., Mikael, K., Mikos, N., Milenkovic, B., Mitsias, D., Moalla, B., Moda, G., Martinez, M. D. M., Mohammad, Y., Moin, M., Molimard, M., Momas, I., Monaco, A., Montefort, S., Mora, D., Morais-Almeida, M., Mosges, R., Mostafa, B. E., Munter, L., Muraro, A., Murray, R., Mustakov, T., Naclerio, R., Nadif, R., Nakonechna, A., Namazova-Baranova, L., Navarro-Locsin, G., Neffen, H., Nekam, K., Neou, A., Nicod, L., Niederberger-Leppin, V., Niedoszytko, M., Nieto, A., Novellino, E., Nunes, E., Nyembue, D., O'Hehir, R., Odjakova, C., Ohta, K., Okamoto, Y., Okubo, K., Oliver, B., Onorato, G. L., Orru, M. P., Ouedraogo, S., Ouoba, K., Paggiaro, P. L., Pagkalos, A., Palaniappan, S. P., Pali-Scholl, I., Palkonen, S., Palmer, S., Bunu, C. P., Panzner, P., Papanikolaou, V., Papi, A., Paralchev, B., Paraskevopoulos, G., Park, H. S., Passalacqua, G., Patella, V., Pavord, I., Pawankar, R., Pedersen, S., Peleve, S., Pereira, A., Perez, T., Pham-Thi, N., Pigearias, B., Pin, I., Piskou, K., Pitsios, C., Pitsios, K., Plavec, D., Poethig, D., Pohl, W., Susic, A. P., Popov, T. A., Portejoie, F., Potter, P., Poulsen, L., Prados-Torres, A., Prarros, F., Price, D., Prokopakis, E., Puy, R., Rabe, K., Raciborski, F., Ramos, J., Recto, M. T., Reda, S. M., Regateiro, F., Reider, N., Reitsma, S., Repka-Ramirez, S., Rimmer, J., Yeverino, D. R., Rizzo, J. A., Robalo-Cordeiro, C., Roberts, G., Roche, N., Gonzalez, M. R., Zagal, E. R., Rolland, C., Roller-Wirns-berger, R., Rodriguez, M. R., Romano, A., Rombaux, P., Romualdez, J., Rosado-Pinto, J., Rosario, N., Rosenwasser, L., Rottem, M., Rouadi, P., Rovina, N., Sinur, I. R., Ruiz, M., Segura, L. T. R., Ryan, D., Sagara, H., Sakai, D., Sakurai, D., Saleh, W., Salimaki, J., Salina, H., Samitas, K. -N., Coronel, M. G. S., Sanchez-Borges, M., Sanchez-Lopez, J., Sarafoleanu, C., Serpa, F. S., Sastre-Dominguez, J., Scadding, G., Scheire, S., Schmid-Grendelmeier, P., Schuhl, J. F., Schunemann, H., Schvalbova, M., Scichilone, N., Sepulveda, C., Serrano, E., Sheikh, A., Shields, M., Shishkov, V., Siafakas, N., Simeonov, A., Simons, E. F., Sisul, J. C., Sitkauskiene, B., Skrindo, I., Soklic, T., Sole, D., Sooronbaev, T., Soto-Martinez, M., Sova, M., Spertini, F., Spranger, O., Stamataki, S., Stefanaki, L., Stellato, C., Stelmach, R., Sterk, P., Strandberg, T., Stute, P., Subramaniam, A., Ulrik, C. S., Sutherland, M., Sylvestre, S., Syrigou, A., Barata, L. T., Takovska, N., Tan, R., Tan, F., Tan, V., Tang, I. P., Taniguchi, M., Tannert, L., Tattersall, J., Teixeira, M. D. C., Thijs, C., Thomas, M., To, T., Todo-Bom, A. M., Togias, A., Tomazic, P. -V., Toppila-Salmi, S., Toskala, E., Triggiani, M., Triller, N., Triller, K., Tsiligianni, I., Ulmeanu, R., Urbancic, J., Pereira, M. U., Vachova, M., Valdes, F., Valenta, R., Rostan, M. V., Valero, A., Vallianatou, M., Valovirta, E., Eerd, M. V., Ganse, E. V., Hage, M., Vandenplas, O., Vasankari, T., Vassileva, D., Ventura, M. T., Vera-Munoz, C., Vicheva, D., Vichyanond, P., Vidgren, P., Viegi, G., Vogelmeier, C., Hertzen, L. V., Vontetsianos, T., Vourdas, D., Wagenmann, M., Walker, S., Wallace, D., Wang, D. Y., Waserman, S., Wickman, M., Williams, S., Williams, D., Wilson, N., Woo, K., Wright, J., Wroczynski, P., Xepapadaki, P., Yakovliev, P., Yamaguchi, M., Yan, K., Yap, Y. Y., Yawn, B., Yiallouros, P., Yoshihara, S., Young, I., Yusuf, O. B., Zaidi, A., Zaitoun, F., Zar, H., Zernotti, M., Zhang, L., Zhong, N., and Zidarn, M.

Published
2020

79. Use of biologicals in allergic and type 2 inflammatory diseases in the current COVID-19 pandemic [Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie]

Author

Klimek, L. Pfaar, O. Worm, M. Eiwegger, T. Hagemann, J. Ollert, M. Untersmayr, E. Hoffmann-Sommergruber, K. Vultaggio, A. Agache, I. Bavbek, S. Bossios, A. Casper, I. Chan, S. Chatzipetrou, A. Vogelberg, C. Firinu, D. Kauppi, P. Kolios, A. Kothari, A. Matucci, A. Palomares, O. Szépfalusi, Z. Pohl, W. Hötzenecker, W. Rosenkranz, A.R. Bergmann, K.-C. Bieber, T. Buhl, R. Buters, J. Darsow, U. Keil, T. Kleine-Tebbe, J. Lau, S. Maurer, M. Merk, H. Mösges, R. Saloga, J. Staubach, P. Jappe, U. Rabe, K.F. Rabe, U. Vogelmeier, C. Biedermann, T. Jung, K. Schlenter, W. Ring, J. Chaker, A. Wehrmann, W. Becker, S. Freudelsperger, L. Mülleneisen, N. Nemat, K. Czech, W. Wrede, H. Brehler, R. Fuchs, T. Tomazic, P.-V. Aberer, W. Fink-Wagner, A.-H. Horak, F. Wöhrl, S. Niederberger-Leppin, V. Pali-Schöll, I. Pohl, W. Roller-Wirnsberger, R. Spranger, O. Valenta, R. Akdis, M. Matricardi, P.M. Spertini, F. Khaltaev, N. Michel, J.-P. Nicod, L. Schmid-Grendelmeier, P. Idzko, M. Hamelmann, E. Jakob, T. Werfel, T. Wagenmann, M. Taube, C. Jensen-Jarolim, E. Korn, S. Hentges, F. Schwarze, J. O'Mahony, L. Knol, E.F. del Giacco, S. Chivato Pérez, T. Bousquet, J. Zuberbier, T. Akdis, C. Jutel, M. Positionspapier des arzteverbands Deutscher Allergologen (AeDA) der Deutschen Gesellschaft fur Allergologie und klinische Immunologie (DGAKI) der Gesellschaft fur Padiatrische Allergologie und Umweltmedizin (GPA) der osterreichischen Gesellschaft fur Allergologie und Immunologie (oGAI) der Luxemburgischen Gesellschaft fur Allergologie und Immunologie (LGAI) der osterreichischen Gesellschaft fur Pneumologie (oGP) Kooperation mit der deutschen, osterreichischen, und schweizerischen ARIA-Gruppe der Europaischen Akademie fur Allergologie und Klinische Immunologie (EAACI)

Published
2020

80. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy [EAACI-Leitlinien zur allergen-spezifischen Immuntherapie: Insektengiftallergie]

Author

Sturm, G.J. Varga, E.-M. Roberts, G. Mosbech, H. Bilo, M.B. Akdis, C.A. Antol'in-Ame'rigo, D. Cichocka-Jarosz, E. Gawlik, R. Jakob, T. Kosnik, M. Lange, J. Mingomataj, E. Mitsias, D.I. Ollert, M. Elberink, J.N.G.O. Pfaar, O. Pitsios, C. Pravettoni, V. Rueff, F. Sin, B.A. Agache, I. Angier, E. Arasi, S. Caldero'n, M.A. Fernandez-Rivas, M. Halken, S. Jutel, M. Lau, S. Pajno, G.B. Van Ree, R. Ryan, D. Spranger, O. Van Wijk, R.G. Dhami, S. Zaman, H. Sheikh, A. Muraro, A.

Published
2020

81. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Author

Agache, I. Beltran, J. Akdis, C. Akdis, M. Canelo-Aybar, C. Canonica, G.W. Casale, T. Chivato, T. Corren, J. Del Giacco, S. Eiwegger, T. Firinu, D. Gern, J.E. Hamelmann, E. Hanania, N. Mäkelä, M. Hernández-Martín, I. Nair, P. O'Mahony, L. Papadopoulos, N.G. Papi, A. Park, H.-S. Pérez de Llano, L. Posso, M. Rocha, C. Quirce, S. Sastre, J. Shamji, M. Song, Y. Steiner, C. Schwarze, J. Alonso-Coello, P. Palomares, O. Jutel, M.

Abstract

Five biologicals have been approved for severe eosinophilic asthma, a well-recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to standard of care for severe eosinophilic asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma-related outcomes were evaluated for each of the biologicals. The risk of bias and the certainty of the evidence were assessed using GRADE. 19 RCTs (three RCTs for benralizumab, three RCTs for dupilumab, three RCTs for mepolizumab, five RCTs for omalizumab and five RCTs for reslizumab), including subjects 12 to 75 years old (except for omalizumab including also subjects 6-11 years old), ranging from 12 to 56 weeks were evaluated. All biologicals reduce exacerbation rates with high certainty of evidence: benralizumab incidence rate ratio (IRR) 0.53 (95% CI 0.39 to 0.72), dupilumab (IRR) 0.43 (95% CI 0.32 to 0.59), mepolizumab IRR 0.49 (95% CI 0.38 to 0.66), omalizumab (IRR) 0.56 (95% CI 0.40 to 0.77) and reslizumab (IRR) 0.46 (95% CI 0.37 to 0.58). Benralizumab, dupilumab and mepolizumab reduce the daily dose of oral corticosteroids (OCS) with high certainty of evidence. All evaluated biologicals probably improve asthma control, QoL and FEV1, without reaching the minimal important difference (moderate certainty). Benralizumab, mepolizumab and reslizumab slightly increase drug-related adverse events (AE) and drug-related serious AE (low to very low certainty of evidence). The incremental cost-effectiveness ratio per quality-adjusted life year value is above the willingness to pay threshold for all biologicals (moderate certainty). Potential savings are driven by decrease in hospitalizations, emergency and primary care visits. There is high certainty that all approved biologicals reduce the rate of severe asthma exacerbations and for benralizumab, dupilumab and mepolizumab for reducing OCS. There is moderate certainty for improving asthma control, QoL, FEV1. More data on long-term safety are needed together with more efficacy data in the paediatric population. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2020

82. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

Author

Agache, I. Song, Y. Rocha, C. Beltran, J. Posso, M. Steiner, C. Alonso-Coello, P. Akdis, C. Akdis, M. Canonica, G.W. Casale, T. Chivato, T. Corren, J. del Giacco, S. Eiwegger, T. Firinu, D. Gern, J.E. Hamelmann, E. Hanania, N. Mäkelä, M. Martín, I.H. Nair, P. O'Mahony, L. Papadopoulos, N.G. Papi, A. Park, H.-S. Pérez de Llano, L. Quirce, S. Sastre, J. Shamji, M. Schwarze, J. Canelo-Aybar, C. Palomares, O. Jutel, M.

Abstract

Dupilumab, a fully human monoclonal antibody against interleukin-4 receptor α, is approved as add-on maintenance treatment for inadequately controlled type 2 severe asthma. This systematic review evaluated the efficacy, safety and economic impact of dupilumab compared to standard of care for uncontrolled severe asthma. PubMed, EMBASE and Cochrane Library were searched for RCTs and health economic evaluations. Critical and important asthma-related outcomes were evaluated. The risk of bias and the certainty of the evidence were assessed using GRADE. Three RCTs including 2735 subjects >12 years old and 24-52 weeks of follow-up were included. Dupilumab reduced with high certainty severe asthma exacerbations (Incidence rate ratio 0.51; 95% CI 0.45-0.59) and the percentage use of oral corticosteroid use (mean difference (MD) −28.2 mg/d; 95% CI −40.7 to −15.7). Asthma control (ACQ-5), quality of life (AQLQ) and rescue medication use [puffs/d] improved, without reaching the minimal important clinical difference: ACQ-5 MD −0.28 (95% CI −0.39 to −0.17); AQLQ MD +0.28 (95% CI 0.20-0.37); and rescue medication MD −0.35 (95% CI −0.73 to +0.02). FEV1 increased (MD +0.15; 95% CI +0.11 to +0.18) (moderate certainty). There was an increased rate of dupilumab-related adverse events (AEs) (moderate certainty) and of drug-related serious AEs (low certainty). The incremental cost-effectiveness ratio of dupilumab versus standard therapy was 464 000$/QALY (moderate certainty). More data on long-term safety are needed both for children and for adults, together with more efficacy data in the paediatric population. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2020

83. Allergen immuntherapy in the current COVID-19 pandemic - A position paper of ARIA, EAACI, AeDA, DGAKI, and GPA

Author

Klimek, L., Pfaar, O., Worm, M., Bergmann, K-C, Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., Maurer, M., Merk, H., Moesges, R., Saloga, J., Staubach, P., Stute, P., Rabe, K., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Muelleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P-, V, Aberer, W., Fink-Wagner, A., Horak, F., Woehrl, S., Niederberger-Leppin, V, Pali-Schoell, I, Pohl, W., Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Akdis, C., Hoffmann-Sommergruber, K., Jutel, M., Matricardi, P., Spertini, F., Khaltaev, N., Michel, J-P, Nicod, L., Schmid-Grendelmeier, P., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Bousquet, J., Zuberbier, T., Vogelberg, C., Gerstlauer, M., Klimek, L., Pfaar, O., Worm, M., Bergmann, K-C, Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., Maurer, M., Merk, H., Moesges, R., Saloga, J., Staubach, P., Stute, P., Rabe, K., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Muelleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P-, V, Aberer, W., Fink-Wagner, A., Horak, F., Woehrl, S., Niederberger-Leppin, V, Pali-Schoell, I, Pohl, W., Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Akdis, C., Hoffmann-Sommergruber, K., Jutel, M., Matricardi, P., Spertini, F., Khaltaev, N., Michel, J-P, Nicod, L., Schmid-Grendelmeier, P., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Bousquet, J., Zuberbier, T., Vogelberg, C., and Gerstlauer, M.

Published
2020

84. Use of biologicals in allergic and type 2 inflammatory diseases in the current COVID 19 pandemic

Author

Klimek, L., Pfaar, O., Worm, M., Eiwegger, T., Hagemann, J., Ollert, M., Untersmayr, E., Hoffmann-Sommergruber, K., Vultaggio, A., Agache, I, Bavbek, S., Bossios, A., Casper, I, Chan, S., Chatzipetrou, A., Vogelberg, C., Firinu, D., Kauppi, P., Kolios, A., Kothari, A., Matucci, A., Palomares, O., Szepfalusi, Z., Pohl, W., Hoetzenecker, W., Rosenkranz, A., Bergmann, K-C, Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., Maurer, M., Merk, H., Moesges, R., Saloga, J., Staubach, P., Jappe, U., Rabe, C., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Freudelsperger, L., Muelleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P-, V, Aberer, W., Fink-Wagner, A., Horak, F., Woehrl, S., Niederberger-Leppin, V, Pali-Schoell, I, Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Matricardi, P. M., Spertini, F., Khaltaev, N., Michel, J-P, Nicod, L., Schmid-Grendelmeier, P., Idzko, M., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Jensen-Jarolim, E., Korn, S., Hentges, F., Schwarze, J., OMahony, L., Knol, E., del Giacco, S., Chivato Perez, T., Bousquet, J., Zuberbier, T., Akdis, C., Jutel, M., Klimek, L., Pfaar, O., Worm, M., Eiwegger, T., Hagemann, J., Ollert, M., Untersmayr, E., Hoffmann-Sommergruber, K., Vultaggio, A., Agache, I, Bavbek, S., Bossios, A., Casper, I, Chan, S., Chatzipetrou, A., Vogelberg, C., Firinu, D., Kauppi, P., Kolios, A., Kothari, A., Matucci, A., Palomares, O., Szepfalusi, Z., Pohl, W., Hoetzenecker, W., Rosenkranz, A., Bergmann, K-C, Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., Maurer, M., Merk, H., Moesges, R., Saloga, J., Staubach, P., Jappe, U., Rabe, C., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Freudelsperger, L., Muelleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P-, V, Aberer, W., Fink-Wagner, A., Horak, F., Woehrl, S., Niederberger-Leppin, V, Pali-Schoell, I, Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Matricardi, P. M., Spertini, F., Khaltaev, N., Michel, J-P, Nicod, L., Schmid-Grendelmeier, P., Idzko, M., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Jensen-Jarolim, E., Korn, S., Hentges, F., Schwarze, J., OMahony, L., Knol, E., del Giacco, S., Chivato Perez, T., Bousquet, J., Zuberbier, T., Akdis, C., and Jutel, M.

Published
2020

85. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA- EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)

Author

Pfaar, O., Klimek, L., Worm, M., Bergmann, K-C, Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., Maurer, M., Merk, H., Mosges, R., Saloga, J., Staubach, P., Stute, P., Rabe, K., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Muelleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P-, V, Aberer, W., Fink-Wagner, A., Horak, F., Woehrl, S., Niederberger-Leppin, V, Pali-Schoell, I, Pohl, W., Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Akdis, C., Hoffmann-Sommergruber, K., Jutel, M., Matricardi, P., Spertini, F., Khaltaev, N., Michel, J-P, Nicod, L., Schmid-Grendelmeier, P., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Gerstlauer, M., Vogelberg, C., Bousquet, J., Zuberbier, T., Pfaar, O., Klimek, L., Worm, M., Bergmann, K-C, Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., Maurer, M., Merk, H., Mosges, R., Saloga, J., Staubach, P., Stute, P., Rabe, K., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Muelleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P-, V, Aberer, W., Fink-Wagner, A., Horak, F., Woehrl, S., Niederberger-Leppin, V, Pali-Schoell, I, Pohl, W., Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Akdis, C., Hoffmann-Sommergruber, K., Jutel, M., Matricardi, P., Spertini, F., Khaltaev, N., Michel, J-P, Nicod, L., Schmid-Grendelmeier, P., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Gerstlauer, M., Vogelberg, C., Bousquet, J., and Zuberbier, T.

Published
2020

86. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

Author

Bousquet, J, Anto, JM, Iaccarino, G, Czarlewski, W, Haahtela, T, Anto, A, Akdis, CA, Blain, H, Canonica, GW, Cardona, V, Cruz, AA, Illario, M, Ivancevich, JC, Jutel, M, Klimek, L, Kuna, P, Laune, D, Larenas-Linnemann, D, Mullol, J, Papadopoulos, NG, Pfaar, O, Samolinski, B, Valiulis, A, Yorgancioglu, A, Zuberbier, T, ARIA group, Bousquet, J, Anto, JM, Iaccarino, G, Czarlewski, W, Haahtela, T, Anto, A, Akdis, CA, Blain, H, Canonica, GW, Cardona, V, Cruz, AA, Illario, M, Ivancevich, JC, Jutel, M, Klimek, L, Kuna, P, Laune, D, Larenas-Linnemann, D, Mullol, J, Papadopoulos, NG, Pfaar, O, Samolinski, B, Valiulis, A, Yorgancioglu, A, Zuberbier, T, and ARIA group

Abstract

Reported COVID-19 deaths in Germany are relatively low as compared to many European countries. Among the several explanations proposed, an early and large testing of the population was put forward. Most current debates on COVID-19 focus on the differences among countries, but little attention has been given to regional differences and diet. The low-death rate European countries (e.g. Austria, Baltic States, Czech Republic, Finland, Norway, Poland, Slovakia) have used different quarantine and/or confinement times and methods and none have performed as many early tests as Germany. Among other factors that may be significant are the dietary habits. It seems that some foods largely used in these countries may reduce angiotensin-converting enzyme activity or are anti-oxidants. Among the many possible areas of research, it might be important to understand diet and angiotensin-converting enzyme-2 (ACE2) levels in populations with different COVID-19 death rates since dietary interventions may be of great benefit.

Published
2020

87. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries?

Author

Bousquet, J, Anto, JM, Iaccarino, G, Czarlewski, W, Haahtela, T, Anto, A, Akdis, CA, Blain, H, Walter Canonica, G, Cardona, V, Cruz, AA, Illario, M, Ivancevich, JC, Jutel, M, Klimek, L, Kuna, P, Laune, D, Larenas-Linnemann, D, Mullol, J, Papadopoulos, NG, Pfaar, O, Samolinski, B, Valiulis, A, Yorgancioglu, A, Zuberbier, T, ARIA group, Bousquet, J, Anto, JM, Iaccarino, G, Czarlewski, W, Haahtela, T, Anto, A, Akdis, CA, Blain, H, Walter Canonica, G, Cardona, V, Cruz, AA, Illario, M, Ivancevich, JC, Jutel, M, Klimek, L, Kuna, P, Laune, D, Larenas-Linnemann, D, Mullol, J, Papadopoulos, NG, Pfaar, O, Samolinski, B, Valiulis, A, Yorgancioglu, A, Zuberbier, T, and ARIA group

Abstract

[This corrects the article DOI: 10.1186/s13601-020-00323-0.].

Published
2020

88. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

Author

Bousquet J, Anto JM, Iaccarino G, Czarlewski W, Haahtela T, Anto A, Akdis CA, Blain H, Canonica GW, Cardona V, Cruz AA, Illario M, Ivancevich JC, Jutel M, Klimek L, Kuna P, Laune D, Larenas-Linnemann D, Mullol J, Papadopoulos NG, Pfaar O, Samolinski B, Valiulis A, Yorgancioglu A, Zuberbier T, ARIA group, Bousquet J, Anto JM, Iaccarino G, Czarlewski W, Haahtela T, Anto A, Akdis CA, Blain H, Canonica GW, Cardona V, Cruz AA, Illario M, Ivancevich JC, Jutel M, Klimek L, Kuna P, Laune D, Larenas-Linnemann D, Mullol J, Papadopoulos NG, Pfaar O, Samolinski B, Valiulis A, Yorgancioglu A, Zuberbier T, and ARIA group

Abstract

Reported COVID-19 deaths in Germany are relatively low as compared to many European countries. Among the several explanations proposed, an early and large testing of the population was put forward. Most current debates on COVID-19 focus on the differences among countries, but little attention has been given to regional differences and diet. The low-death rate European countries (e.g. Austria, Baltic States, Czech Republic, Finland, Norway, Poland, Slovakia) have used different quarantine and/or confinement times and methods and none have performed as many early tests as Germany. Among other factors that may be significant are the dietary habits. It seems that some foods largely used in these countries may reduce angiotensin-converting enzyme activity or are anti-oxidants. Among the many possible areas of research, it might be important to understand diet and angiotensin-converting enzyme-2 (ACE2) levels in populations with different COVID-19 death rates since dietary interventions may be of great benefit.

Published
2020

89. In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan - An EAACI position paper

Author

Klimek, L, Hoffmann, H J, Kalpaklioglu, A F, Demoly, P, Agache, L, Popov, T, Muraro, A, Schmid-Grendelmeier, P, Bonini, S, Bonertz, A, Mahler, V, Vieths, S, Pfaar, O, Zuberbier, T, Jutel, M, Schmidt-Weber, C, Hellings, P, Dreborg, S, Bonini, Matteo, Brough, H A, Bousquet, J, Hoffmann-Sommergruber, K, Palomares, O, Ollert, M, Shamji, M H, Cardona, V, Bonini, M (ORCID:0000-0002-3042-0765), Klimek, L, Hoffmann, H J, Kalpaklioglu, A F, Demoly, P, Agache, L, Popov, T, Muraro, A, Schmid-Grendelmeier, P, Bonini, S, Bonertz, A, Mahler, V, Vieths, S, Pfaar, O, Zuberbier, T, Jutel, M, Schmidt-Weber, C, Hellings, P, Dreborg, S, Bonini, Matteo, Brough, H A, Bousquet, J, Hoffmann-Sommergruber, K, Palomares, O, Ollert, M, Shamji, M H, Cardona, V, and Bonini, M (ORCID:0000-0002-3042-0765)

Published
2020

90. Correction to: Highlights and recent developments in skin allergy and related diseases in EAACI journals (2018)

Author

Akdis, C A, Bousquet, J; https://orcid.org/0000-0001-9226-7762, Grattan, C E, Eigenmann, P A, Hofmann-Sommergruber, K, Agache, I, Jutel, M, Akdis, C A, Bousquet, J; https://orcid.org/0000-0001-9226-7762, Grattan, C E, Eigenmann, P A, Hofmann-Sommergruber, K, Agache, I, and Jutel, M

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Published
2020

91. Highlights and recent developments in allergic diseases in EAACI journals (2019)

Author

Bousquet, J; https://orcid.org/0000-0001-9226-7762, Grattan, C E, Akdis, C A, Eigenmann, P A, Hoffmann-Sommergruber, K, Agache, I, Jutel, M, Bousquet, J; https://orcid.org/0000-0001-9226-7762, Grattan, C E, Akdis, C A, Eigenmann, P A, Hoffmann-Sommergruber, K, Agache, I, and Jutel, M

Abstract

The European Academy of Allergy and Clinical Immunology (EAACI) owns three journals: Allergy, Pediatric Allergy and Immunology and Clinical and Translational Allergy. One of the major goals of EAACI is to support health promotion in which prevention of allergy and asthma plays a critical role and to disseminate the knowledge of allergy to all stakeholders including the EAACI junior members. There was substantial progress in 2019 in the identification of basic mechanisms of allergic and respiratory disease and the translation of these mechanisms into clinics. Better understanding of molecular and cellular mechanisms, efforts for the development of biomarkers for disease prediction, novel prevention and intervention studies, elucidation of mechanisms of multimorbidities, entrance of new drugs in the clinics as well as recently completed phase three clinical studies and publication of a large number of allergen immunotherapy studies and meta-analyses have been the highlights of the last year.

Published
2020

92. Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives - a report of the European Academy of Allergy and Clinical Immunology (EAACI)

Author

CTI Research, CTI, MS Dermatologie/Allergologie, Infection & Immunity, Sokolowska, M, Lukasik, Z, Agache, I, Akdis, C A, Akdis, D, Akdis, M, Barcik, W, Brough, H, Eiwegger, T, Eliaszewicz, A, Eyerich, S, Feleszko, W, Gomez Casado, C, Hoffmann-Sommergruber, K, Janda, J, Jiménez-Saiz, R, Jutel, M, Knol, E, Kortekaas Krohn, I, Kothari, A, Makowska, J, Moniuszko, M, Morita, H, O'Mahony, L, Nadeau, K, Ozdemir, C, Pali-Schöll, I, Palomares, O, Papaleo, F, Prunicki, M, Schmidt-Weber, C B, Sediva, A, Schwarze, J, Shamji, M H, Tramper-Stranders, G, van, W, de Veen, R., Untersmayr, E, CTI Research, CTI, MS Dermatologie/Allergologie, Infection & Immunity, Sokolowska, M, Lukasik, Z, Agache, I, Akdis, C A, Akdis, D, Akdis, M, Barcik, W, Brough, H, Eiwegger, T, Eliaszewicz, A, Eyerich, S, Feleszko, W, Gomez Casado, C, Hoffmann-Sommergruber, K, Janda, J, Jiménez-Saiz, R, Jutel, M, Knol, E, Kortekaas Krohn, I, Kothari, A, Makowska, J, Moniuszko, M, Morita, H, O'Mahony, L, Nadeau, K, Ozdemir, C, Pali-Schöll, I, Palomares, O, Papaleo, F, Prunicki, M, Schmidt-Weber, C B, Sediva, A, Schwarze, J, Shamji, M H, Tramper-Stranders, G, van, W, de Veen, R., and Untersmayr, E

Published
2020

98. Prevention and control of childhood asthma and allergy in the EU from the public health point of view: Polish Presidency of the European Union

Author

Samoliński, B., Fronczak, A., Kuna, P., Akdis, C. A., Anto, J. M., Bialoszewski, A. Z., Burney, P. G., Bush, A., Czupryniak, A., Dahl, R., Flood, B., Galea, G., Jutel, M., Kowalski, M. L., Palkonen, S., Papadopoulos, N., Raciborski, F., Sienkiewicz, D., Tomaszewska, A., Von Mutius, E., Willman, D., Włodarczyk, A., Yusuf, O., Zuberbier, T., and Bousquet, J.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results